Point-of-Care Monitoring for Lung Cancer from Exhaled Breath Formaldehyde via Luminescent Metal-Organic Frameworks.

ACS Sens

Dongguan Key Laboratory of Interdisciplinary Science for Advanced Materials and Large-Scale Scientific Facilities, School of Physical Sciences, Great Bay University, Dongguan, Guangdong 523000, China.

Published: June 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The identification of specific markers in exhaled gas from individuals with lung cancer has significantly enhanced the feasibility of early lung cancer screening. This paper presents the synthesis of a 2D Cu-BDC-NH nanosheet at room temperature, which has been applied for the noninvasive diagnosis and point-of-care test (POCT) of lung cancer. During this approach, the hydrazine group in the ligand molecule was employed to enhance the intrinsic fluorescence of Cu-BDC-NH through a Schiff base reaction with formaldehyde (HCHO), thereby reducing the detection limits of HCHO gas and aqueous solution (25 ppb and 0.316 μM). As a proof of concept, Cu-BDC-NH was successfully applied to the early screening of lung cancer patients with an accuracy of 97.45%. The results indicate that the established breath analysis method provides a viable alternative for lung cancer screening.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acssensors.5c00476DOI Listing

Publication Analysis

Top Keywords

lung cancer
24
cancer screening
8
lung
6
cancer
6
point-of-care monitoring
4
monitoring lung
4
cancer exhaled
4
exhaled breath
4
breath formaldehyde
4
formaldehyde luminescent
4

Similar Publications

Objective: This study aimed to probe the role of Shenling Baizhu powder (SLBZP) in inhibiting breast cancer (BC) lung metastasis, focusing on epithelial-to-mesenchymal transition (EMT) and ferroptosis.

Methods: BC 4T1 cells were treated with low (3.13 µg/mL) and high (12.

View Article and Find Full Text PDF

Nanomedicine-Mediated Therapies to Target Cancer Stem Cells: An Emerging Technology.

Crit Rev Ther Drug Carrier Syst

January 2025

Department of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, India.

Cancer stem cells (CSCs) are a category of cancer cells endowed with the ability to renew themselves, undergo unregulated growth, and exhibit a differentiation capacity akin to that of normal stem cells. CSCs have been linked with tumor metastasis and cancer recurrence due to their ability to elude immune monitoring. As a result, targeting CSCs specifically may improve the efficacy of cancer therapy.

View Article and Find Full Text PDF

The Burden of Cancer and Precancerous Conditions Among Transgender Individuals in a Large Health Care Network: Retrospective Cohort Study.

JMIR Cancer

September 2025

Department of Health Outcomes and Biomedical Informatics, University of Florida, 1889 Museum Road, Suite 7000, Gainesville, FL, 32611, United States, 1 352 294-5969.

Background: Disparities in cancer burden between transgender and cisgender individuals remain an underexplored area of research.

Objective: This study aimed to examine the cumulative incidence and associated risk factors for cancer and precancerous conditions among transgender individuals compared with matched cisgender individuals.

Methods: We conducted a retrospective cohort study using patient-level electronic health record (EHR) data from the University of Florida Health Integrated Data Repository between 2012 and 2023.

View Article and Find Full Text PDF

Usnic acid, a compound from Usneae Filum, has shown notable antitumor effects. Nevertheless, the mechanism of its anti-NSCLC action remains incompletely elucidated. This study used metabolomics, network pharmacology, molecular docking, and dynamics simulation to investigate usnic acid's potential mechanism on NSCLC utilizing A549 cell samples.

View Article and Find Full Text PDF

Lymphangioleiomyomatosis (LAM) is a rare lung disease caused by hyperactivation of the mechanistic/mammalian target of rapamycin 1 (mTORC1) growth pathway in a subset of mesenchymal lung cells. Histopathologically, LAM lesions have been described as immature smooth muscle-like cells positive for the immature melanocytic marker HMB45/PMEL/gp100 and phosphorylated ribosomal protein S6 (pS6). Advances in single cell sequencing (scRNA-seq) technology allowed us to group LAM cells according to their expression of cancer stem cell (CSC) genes and identify three clusters: a high CSC-like state (SLS), an intermediate state, and a low CSC-like inflammatory state (IS).

View Article and Find Full Text PDF